secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corbus Pharmaceuticals Holdings, Inc. (CRBP)
CIK:        0001595097
Form:       8-K
Filed at:   2024-06-03T23:59:59+00:00
Accession:  0000950170-24-067651
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corbus reports Phase 1 data for CRB-701 at ASCO: 44% ORR in mUC, 43% in cervical cancer
--------------------------------------------------------------------------------

- 44% ORR and 78% DCR in mUC (n=9), 43% ORR and 86% DCR in cervical cancer (n=7) at doses ≥1.2 mg/Kg.
- No DLTs or grade 4/5 AEs observed to date; single grade 1 neuropathy (resolved) and 3 skin rashes (resolved).
- Free MMAE levels lower than enfortumab vedotin across all doses up to 4.5 mg/Kg.
- Enrollment expanded to 37 patients (25 evaluable); US phase 1 completing Q4 2024, data Q1 2025.
- Preventative eye measures introduced after two grade 3 corneal disorders; no further cases at 4.5 mg/Kg.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595097/000095017024067651/0000950170-24-067651-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595097/000095017024067651/crbp-20240601.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-067651

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer